Compound comprising proton pump inhibitor and gastric mucosa protective agent and application of compound

Abstract

The invention provides a compound comprising a proton pump inhibitor and a gastric mucosa protective agent and an application of the compound. The compound comprises the proton pump inhibitor and the gastric mucosa protective agent and can be directly mixed or indirectly connected through hydrogen bonds, co-crystallized sodium hydrate formed by hydrogen bond connection is more stable in property, and pharmacokinetic property is remarkably improved. Although the proton pump inhibitor and the gastric mucosa protective agent are different in action mechanism, the compound formed by the proton pump inhibitor and the gastric mucosa protective agent has unexpected synergistic effects and has a positive application prospect in the field of digestive ulcer and gastrointestinal bleeding treatment.

Description

technical field [0001] The invention belongs to the field of drugs for treating digestive system diseases, and in particular relates to a compound composed of a proton pump inhibitor and a gastric mucosal protective agent and its application. Background technique [0002] Digestive system disease is a relatively common disease. The course of the disease is mostly chronic and recurrent. The total incidence accounts for 10% to 20% of the total population. The main diseases include acute gastritis, chronic gastritis, peptic ulcer, functional dyspepsia, etc. . Among them, functional dyspepsia and peptic ulcer are the most common. [0003] Peptic ulcers mainly refer to chronic ulcers that occur in the stomach and duodenum, namely gastric ulcers and duodenal ulcers, which are named after the occurrence and formation of ulcers are related to the digestion of gastric acid-pepsin. The initial symptoms are similar to those of functional dyspepsia, such as chronic or periodic pain in...

AI Technical Summary

Problems solved by technology

[0007] ①Slow onset

[0008] ②Acid suppression instability

[0009] ③There are large individual differences in PPIs treatment

[0011] ⑤ Incomplete acid suppression, manifested as nocturnal acid breakthrough phenomenon; in addition, the long-term inhibition of gastric acid secretion by PPIs may cause hypergastrinemia, which further leads to gastric mucosa or precancerous lesions of gastric cancer

The therapeutic effect of the composition on peptic ulcer and gastrointestinal bleeding is still not ideal, and the medicine takes effect slowly, and there is a serious peak-valley phenomenon

Images